TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07822334: A Phase I, Randomized, Investigator and Participant-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of R

Sponsor: Hoffmann-La Roche · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 104 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT07822334 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07822334 Rescue Dossier →